Global Stem Cells Group has announced the opening of two new stem cell centers in the cities of Arica and Iquique in northern Chile. The new centers are the latest part of Global Stem Cells Groups’ expansion efforts in Latin America.
MIAMI (PRWEB) NOVEMBER 30, 2015
Global Stem Cells Group announced the opening of a new core patient care hub with the opening of two new clinics in the cities of Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America.
Both the Arica and Iquique clinics offer the most advanced protocols and techniques in stem cell medicine to patients from around the world.
The clinics will be headed by Victor Perez, M.D. and Duval Aguirre, M.D.
Global Stem Cells Group, is expanding its clinical presence throughout Latin America and worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics. The new Arica and Iquique clinics are certified for the medical tourism market.
GSCG is committed to the highest standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.
For more information, visit the Global Stem Cells Group website, Email bnovas(at)stemcellsgroup(dot)com, or call 
305-560-5337.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
